Navigation Links
Early breast cancer has risks with it!

According to a new study of women with early stage, localized breast cancer new patterns and risk factors for invasive disease have been identified that may influence how patients are treated. //

Data from 37,692 DCIS and 4,490 LCIS patients from 1988 to 2002 was reviewed by Cancer Research Centre in Seattle to identify demographic and tumour characteristics that are risk factors for invasive disease and the pattern of invasive disease that DCIS and LCIS develop.

The authors noted that LCIS patients were at greater risk than DCIS patients for invasive lobular carcinoma (ILC). This infers LCIS to be a precursor lesion to ILC, rather than simply a risk factor. Specifically, LCIS patients were five times more likely to develop ILC and slightly less likely to develop invasive ductal carcinoma (IDC) compared to DCIS patients. Additional finding was that LCIS patients had higher rates of ipsilateral invasive breast cancer, but similar rates of contralateral invasive breast cancer, compared to DCIS patients suggesting that "localized treatment for LCIS may be warranted.

Among DCIS patients, women under 50 years old as well as Hispanic and African-American women were at greater risk for advanced stage invasive breast cancer, which is a more lethal form of the disease, than older and Caucasian women.

This study can be a potential guiding light in in situ treatments but also risk stratification and follow-up recommendations for women with early stage breast cancer.


'"/>




Page: 1

Related medicine news :

1. Early detection of prostate cancer
2. Early detection of heart attack
3. Early puberty linked to nutrition
4. Early Clue to Down Syndrome
5. Early delivery can prevent cancer
6. Early puberty more resistance
7. Early menopause- The cause
8. Early menopause- The cause
9. Early Warning System For Breast Cancer
10. Early therapy aids eyesight
11. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Early breast cancer has risks with

(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...eatment given to people bitten by snakes or dogs. ...ission//. Africa, Latin America and Asia are the ...bite and scorpion stings. When it comes to snake b...wn as many of them prefer home remedies to hospita...
...sease. Yet recent studies have shown that the chan...es such as diet and exercise//, the chances of sur...rld Cancer Research Fund is putting around 50,000 ...ried out by Dundee University, Scotland. The thre...
In Search of Truth - 'Lie Detector
... women’s hospital in Vancouver, Canada last weeken...bies have a fair chance of survival//. Parents o...e infants and making them breathe on their own are...ctors now. Each of these babies weighed around 1...
Other Medicine News:Health News:In Search of Truth - 'Lie Detector 2Health News:In Search of Truth - 'Lie Detector 3Health News:In Search of Truth - 'Lie Detector 4
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
(Date:7/22/2008)...- Nonin Medical, a leading innovator,of physiologi...as entered,the clinical testing phase with its bre...turation. Today,s most common application for this...gional blood oxygenation,in the brain -- cerebral ...n ongoing clinical study at the,Duke University Me...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Is Tap Water Safe for Your Dog 3F 20799 1Is Tap Water Safe for Your Dog 3F 20799 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 1Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 3Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 4Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 1Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 1IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 3IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 4IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 5
...wire/ -- Results from,the primary analysis of a ra...owed that 77 percent of treatment-experienced HIV-...600 mg tablets with,100 mg ritonavir (PREZISTA/r) ...(OBR) of antiretroviral (ARV) agents, reached a,pl...ared to 68,percent of patients taking Kaletra(R)1 ...
...ire-FirstCall/ --,Genzyme Corp. announced top-line... studies to assess the safety and efficacy of,tole...polymer,therapy for patients with Clostridium diff... 3 study of tolevamer liquid is fully,enrolled and...irst Phase 3 study known as the Polymer Alternativ...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4
...eeds I-125 are brachytherapy sources which are imp...mors, especially in the prostate. The seeds remain...ic effect, i.e. after radioactive decay is complet...ey are supplied in a sterile form. Isoseeds I-125 ...
...mirrors for complete anterior chamber angle viewin...or easy handling and stability. Choice large or sm...llows static or dynamic gonioscopy without methylc... coating protects mirrors and is compatible with m...
Three mirrors of 64, 67 and 73 and a small diameter contact surface for use without methylcellulose. The fundus can be viewed through the central axis of the lens. Multi-layer polymer coating protect
West lacrimal cannula blunt tip with side port.
Medicine Products: